CareDx Inc
CDNA12.650USD
+0.430+3.52%
Market hours （ET）Quotes delayed by 15 min
701.60MMarket Cap
11.92P/E TTM
More Details of CareDx Inc Company
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Company Info
Ticker SymbolCDNA
Company nameCareDx Inc
IPO dateJul 17, 2014
CEOMr. John W. Hanna
Number of employees644
Security typeOrdinary Share
Fiscal year-endJul 17
Address8000 Marina Blvd
CityBRISBANE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94005
Phone14152872300
Websitehttps://www.caredx.com/
Ticker SymbolCDNA
IPO dateJul 17, 2014
CEOMr. John W. Hanna
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
143.65K
+0.86%
Jessica Meng
Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
114.33K
+117.46%
Mr. Abhishek Jain
Mr. Abhishek Jain
Chief Financial Officer
Chief Financial Officer
110.14K
-8.07%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
38.58K
+45.71%
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
30.76K
-0.89%
Caroline Corner
Caroline Corner
Investor Relations
Investor Relations
--
--
Ms. Jennifer Foley
Ms. Jennifer Foley
Chief Product Officer
Chief Product Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
143.65K
+0.86%
Jessica Meng
Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
114.33K
+117.46%
Mr. Abhishek Jain
Mr. Abhishek Jain
Chief Financial Officer
Chief Financial Officer
110.14K
-8.07%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
61.92M
0.00%
Digital and other revenue
11.95M
0.00%
Product revenue
10.81M
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
79.86M
0.00%
Rest of the world
4.82M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
61.92M
0.00%
Digital and other revenue
11.95M
0.00%
Product revenue
10.81M
0.00%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.66%
BlackRock Institutional Trust Company, N.A.
7.56%
State Street Global Advisors (US)
4.46%
Baron Capital Management, Inc.
3.93%
Gagnon Securities LLC
3.83%
Other
71.55%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.66%
BlackRock Institutional Trust Company, N.A.
7.56%
State Street Global Advisors (US)
4.46%
Baron Capital Management, Inc.
3.93%
Gagnon Securities LLC
3.83%
Other
71.55%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
44.53%
Investment Advisor
41.96%
Hedge Fund
10.10%
Individual Investor
3.41%
Research Firm
2.92%
Pension Fund
0.57%
Bank and Trust
0.32%
Family Office
0.04%
Venture Capital
0.04%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
455
56.93M
102.27%
-3.71M
2025Q1
463
58.20M
104.56%
-2.86M
2024Q4
457
54.99M
99.23%
-4.48M
2024Q3
452
53.78M
101.72%
-11.43M
2024Q2
424
54.82M
104.96%
-13.18M
2024Q1
450
55.58M
107.13%
-14.92M
2023Q4
462
54.27M
100.29%
-16.52M
2023Q3
493
55.98M
103.34%
-21.97M
2023Q2
517
57.57M
107.02%
-21.82M
2023Q1
532
58.67M
109.28%
-16.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
4.82M
8.66%
-25.66K
-0.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.21M
7.56%
-77.53K
-1.81%
Mar 31, 2025
State Street Global Advisors (US)
2.48M
4.46%
-174.50K
-6.56%
Mar 31, 2025
Baron Capital Management, Inc.
2.19M
3.93%
-17.29K
-0.78%
Mar 31, 2025
Gagnon Securities LLC
1.42M
2.55%
-9.51K
-0.66%
Mar 31, 2025
ARK Investment Management LLC
2.35M
4.22%
-61.72K
-2.56%
Mar 31, 2025
Invesco Advisers, Inc.
1.88M
3.39%
+1.12M
+147.36%
Mar 31, 2025
Ophir Asset Management Pty Ltd
1.62M
2.91%
+1.62M
--
Mar 31, 2025
Hood River Capital Management LLC
1.58M
2.84%
+1.58M
--
Mar 31, 2025
Fred Alger Management, LLC
1.43M
2.58%
-179.38K
-11.11%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
3.93%
Invesco Biotechnology & Genome ETF
2.95%
ROBO Global Healthcare Technology & Innovation ETF
1.43%
Invesco Dorsey Wright Healthcare Momentum ETF
1.43%
Global X Genomics & Biotechnology ETF
1.3%
Franklin Genomic Advancements ETF
0.52%
Main Thematic Innovation ETF
0.42%
SPDR S&P Biotech ETF
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.24%
VictoryShares US Small Mid Cap Value Momentum ETF
0.24%
View more
ARK Genomic Revolution ETF
Proportion3.93%
Invesco Biotechnology & Genome ETF
Proportion2.95%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.43%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.43%
Global X Genomics & Biotechnology ETF
Proportion1.3%
Franklin Genomic Advancements ETF
Proportion0.52%
Main Thematic Innovation ETF
Proportion0.42%
SPDR S&P Biotech ETF
Proportion0.35%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.24%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.24%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
